[Author Disclosure: This content reflects the views of the author and is provided for informational purposes only. It does not constitute investment advice and is not a recommendation or endorsement by BioTech Funding Portal. Any investment decision should be based solely on the issuer’s official offering materials.]
Two months of daily public content. Here's the honest read.
Engagement grew meaningfully once we started introducing the team behind Live-cel and reacting to real industry news, rather than only running scheduled educational content. Our DECODE education series also moved from a manual answer-in-comments format to an integrated Q&A format, based on direct reader feedback.
None of this changes the underlying roadmap: GT-GLA-S03 remains on track toward a mid-2027 IND target, following the FDA INTERACT feedback received in July.
That feedback is preliminary and non-binding, and a Pre-IND meeting is still ahead of us.
Follow along here for specifics as the CMC and clinical planning work progresses.
Follow the whole series: https://bit.ly/Glafabra-TTW
@Brian Christie @Neva West @Brian Christie @Tetsu Yung
Testing the Waters disclosure: We are considering a capital raise and are "Testing the Waters" under Regulation Crowdfunding. No money or other consideration is being solicited, and any that is sent in response will not be accepted. We cannot accept any offer to buy securities, and no part of the purchase price can be received until an offering statement is filed and only through the BioTech Funding Portal platform. Any indication of interest is non-binding and involves no obligation or commitment of any kind.
Register for FREE to comment or continue reading this article. Already registered? Login here.
0